Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Paesmans

Showing results (171-180 of 187) with videos related to

Pageof 19
Sort By:
International Journal of Oncology|May 11, 2011
A phase-ii study testing weekly platinum derivative combination chemotherapy as 2nd-line treatment in patients with advanced small-cell lung-cancerJ Sculier, J Thiriaux, G Bureau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2011
Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countriesK S Saini, C Taylor, A-J Ramirez, et al.
British Journal of Cancer|May 3, 2007
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working PartyT Berghmans, J J Lafitte, J Lecomte, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1996
Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection ProgramA Cometta, T Calandra, H Gaya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2017
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trialL Buisseret, S Pommey, B Allard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancerJ-P Sculier, J-J Lafitte, T Berghmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 1999
A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working PartyJ P Sculier, M Paesmans, J J Lafitte, et al.
ESMO Open|June 12, 2026
Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based studyG Nader-Marta, L Ameye, D Martins-Branco, et al.
The European Respiratory Journal|August 11, 2007
Chemotherapy improves low performance status lung cancer patientsJ P Sculier, J J Lafitte, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2001
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamideA Di Leo, D Larsimont, D Gancberg, et al.
Pageof 19

Showing results (171-180 of 187) with videos related to

Sort By:
Pageof 19
International Journal of Oncology|May 11, 2011
A phase-ii study testing weekly platinum derivative combination chemotherapy as 2nd-line treatment in patients with advanced small-cell lung-cancerJ Sculier, J Thiriaux, G Bureau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2011
Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countriesK S Saini, C Taylor, A-J Ramirez, et al.
British Journal of Cancer|May 3, 2007
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working PartyT Berghmans, J J Lafitte, J Lecomte, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1996
Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection ProgramA Cometta, T Calandra, H Gaya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2017
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trialL Buisseret, S Pommey, B Allard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancerJ-P Sculier, J-J Lafitte, T Berghmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 1999
A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working PartyJ P Sculier, M Paesmans, J J Lafitte, et al.
ESMO Open|June 12, 2026
Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based studyG Nader-Marta, L Ameye, D Martins-Branco, et al.
The European Respiratory Journal|August 11, 2007
Chemotherapy improves low performance status lung cancer patientsJ P Sculier, J J Lafitte, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2001
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamideA Di Leo, D Larsimont, D Gancberg, et al.
Pageof 19